In this article, we will discuss Durvalumab (Warnings-27). So, let’s get started.
Immune-mediated rash or dermatitis occurred in 1.8% (34/1889) of patients receiving Durvalumab, including Grade 3 (0.4%) adverse reactions. Events resolved in 19 of the 34 patients and resulted in permanent discontinuation in 2 patients. Systemic corticosteroids were required in all patients with immune-mediated rash or dermatitis.